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Abstract
Background: This Phase 1/2a study evaluated the safety, immunogenicity, and efficacy of an experimental malaria vaccine
comprised of the recombinant Plasmodium falciparum protein apical membrane antigen-1 (AMA-1) representing the 3D7
allele formulated with either the AS01B or AS02A Adjuvant Systems.
Methodology/Principal Findings: After a preliminary safety evaluation of low dose AMA-1/AS01B (10 mg/0.5 mL) in 5
adults, 30 malaria-naı ¨ve adults were randomly allocated to receive full dose (50 mg/0.5 mL) of AMA-1/AS01B (n=15) or
AMA-1/AS02A (n=15), followed by a malaria challenge. All vaccinations were administered intramuscularly on a 0-, 1-, 2-
month schedule. All volunteers experienced transient injection site erythema, swelling and pain. Two weeks post-third
vaccination, anti-AMA-1 Geometric Mean Antibody Concentrations (GMCs) with 95% Confidence Intervals (CIs) were high:
low dose AMA-1/AS01B 196 mg/mL (103–371 mg/mL), full dose AMA-1/AS01B 279 mg/mL (210–369 mg/mL) and full dose
AMA-1/AS02A 216 mg/mL (169–276 mg/mL) with no significant difference among the 3 groups. The three vaccine
formulations elicited equivalent functional antibody responses, as measured by growth inhibition assay (GIA), against
homologous but not against heterologous (FVO) parasites as well as demonstrable interferon-gamma (IFN-c) responses. To
assess efficacy, volunteers were challenged with P. falciparum-infected mosquitoes, and all became parasitemic, with no
significant difference in the prepatent period by either light microscopy or quantitative polymerase chain reaction (qPCR).
However, a small but significant reduction of parasitemia in the AMA-1/AS02A group was seen with a statistical model
employing qPCR measurements.
Significance: All three vaccine formulations were found to be safe and highly immunogenic. These immune responses did
not translate into significant vaccine efficacy in malaria-naı ¨ve adults employing a primary sporozoite challenge model, but
encouragingly, estimation of parasite growth rates from qPCR data may suggest a partial biological effect of the vaccine.
Further evaluation of the immunogenicity and efficacy of the AMA-1/AS02A formulation is ongoing in a malaria-
experienced pediatric population in Mali.
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Malaria, particularly due to Plasmodium falciparum, is responsible
for an estimated 1–2 million deaths per year [1]. The populations
most affected by malaria are children less than five years of age
and primigravidae [2] living in malaria endemic areas, and
malaria-naı ¨ve individuals traveling to endemic areas. An effective
malaria vaccine, in addition to other available preventive
measures, is critical to mitigating the effects of this disease in
these vulnerable populations.
A malaria vaccine able to prevent infections as well as control
blood stage growth will likely require pre-erythrocytic and
erythrocytic stage components that are able to elicit anti-parasitic
humoral and cell-mediated immune responses [3]. Apical
membrane antigen-1 (AMA-1) is an 83-kDa precursor protein
localized in the micronemes at the apical end of the merozoite, the
erythrocyte-invading stage of the parasite [4]. This precursor is
proteolytically cleaved to form a 66-kDa protein which then
translocates from micronemes to the surface of the merozoite [5]
and as such is thought to mediate merozoite reorientation to the
erythrocyte [6]. AMA-1 has also been found on the surface of
sporozoites and on hepatic merozoites [7]; thus, this ‘‘blood stage’’
antigen may be a target for protective immune responses against
both the invading sporozoite and liver stage of the parasite.
Several studies have shown that anti-AMA-1 antibodies may
play a role in protective immunity in adults living in malaria-
endemic areas, and while these studies did demonstrate cross-
reactivity to heterologous alleles, the degree to which these
antibodies reacted varied [8,9]. Other studies with T-cells from
naturally-exposed subjects have reported proliferation in response
to peptides derived from AMA-1 [10,11]. Preclinical studies in
mice have demonstrated protection (survival with reduced
parasitemia) against the rodent parasite P. chabaudi by active
immunization with homologous recombinant AMA-1 protein
formulated with potent adjuvants, as well as by passive transfer of
immunoglobulin from vaccinated rabbits [12]. Additionally, active
immunization of rhesus monkeys with P. knowlesi AMA-1
adjuvanted in saponin resulted in some animals demonstrating a
delayed prepatent period when challenged with P. knowlesi
schizonts [13]. In Aotus monkeys immunized with P. falciparum
recombinant AMA-1 in complete Freund’s adjuvant, significant
delays in parasitemia after homologous blood stage challenge were
seen as compared to monkeys immunized with a similarly
adjuvanted control malarial antigen [14]. T-cell responses to
AMA-1 were detected in naı ¨ve adult volunteers immunized with
irradiated P. falciparum sporozoites [15], suggesting that AMA-1
may be able to elicit cellular host immune responses to act against
pre-erythrocytic stages of P. falciparum infection.
Two Phase 1 dose-escalation adult vaccine trials have been
completed, one at WRAIR and one in Mali, evaluating FMP2.1,
an AMA-1 recombinant protein vaccine based on the 3D7 allele,
formulated with the GlaxoSmithKline (GSK) proprietary Adju-
vant System, AS02A [16,17]. Both studies demonstrated the
vaccine to be well-tolerated and immunogenic. Recent preclinical
data suggests another GSK Adjuvant System, AS01B, may be
more potent than AS02A, which may translate into improved
efficacy of vaccines adjuvanted with this System [18–20]. The
current Phase 1/2a study was the first to compare the safety and
immunogenicity of an AMA-1-based vaccine in both AS01B and
AS02A Adjuvant Systems, and the first to assess the efficacy of
such a vaccine in malaria-naı ¨ve adults using a homologous
primary sporozoite challenge model [21], thus contributing key
information to the development process of a multi-component
malaria vaccine [22]. Further adding to such a process, the
ongoing Phase 1b and 2b FMP2.1/AS02A pediatric vaccine
studies in Mali, while with a single adjuvant and single AMA-
1allele, will provide valuable information regarding the mecha-
nisms and cross-reactivity of the immune response to P. falciparum
in an endemic pediatric population.
Methods
Participants
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. This study was conducted from September 2006
through April 2007 at the Clinical Trials Center of the Walter
Reed Army Institute of Research (WRAIR), Silver Spring,
Maryland. Healthy malaria-naı ¨ve adults aged 18–50 years were
recruited by non-coercive means in the metropolitan Washington
DC area using inclusion and exclusion criteria described
previously [16].
Ethics
The protocol was reviewed and approved by the WRAIR
Human Use Review Committee, the United States Army Medical
Research and Materiel Command Human Subjects Review
Board, as well as the Western Institutional Review Board,
representing the study partner PATH Malaria Vaccine Initiative
(MVI). Investigators described the protocol to potential volunteers
face to face, and informed consent was obtained by the use of a
written IRB-approved consent form, signed and dated by the
volunteer and the investigator who conducted the informed
consent discussion. This study was conducted according to the
Declaration of Helsinki as well as principles of Good Clinical
Practices under the United States Food and Drug Administration
Investigational New Drug (IND) application BB-13089.
Interventions
The WRAIR recombinant AMA-1 vaccine antigen termed
FMP2.1 was produced in Escherichia coli, Tuner
TM strain (Novagen,
Madison, WI) under current good manufacturing practices
(cGMP) at the WRAIR Pilot Bioproduction Facility and bottled
as a highly purified and lyophilized recombinant protein. The
protein consists of 449 amino acids representing the majority of
the ectodomain (amino acids 83–531) of the 3D7 variant of AMA-
1 with N- and C-terminal His-tags. The method of AMA-1
recombinant protein production and purification has been
described previously [23], and FMP2.1 differs from the method
described only in the E. coli strain used for production. FMP2.1
stability assays and potency tests in mice were carried out
according to International Conference on Harmonisation (ICH)
guidelines and confirmed the vaccine antigen was stable and
potent from date of manufacture through preparation of this
manuscript. The two proprietary Adjuvant Systems used in this
study were produced by GlaxoSmithKline Biologicals (GSK),
Rixensart, Belgium and have been described and evaluated in
multiple vaccine products [24]. AS01B is a liposome-based
Adjuvant System such that the 0.5 mL final dose contains 50 mg
3-deacylated-monophosphoryl lipid A (3-D-MPL), a TLR4 ligand
derived from Salmonella minnesota and 50 mg of QS21, a highly
purified saponin extract from the bark of the South American tree
Quillaja saponaria, while AS02A is based on an oil-in-water
emulsion with the same amounts of 3-D-MPL and QS-21. The
lyophilized FMP2.1 antigen, Lot #1046, was packaged in single
dose vials of approximately 60 mg. For full dose vaccine
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prepackaged Adjuvant Systems AS02A or AS01B, resulting in an
estimated final dose of 50 mg AMA-1 in 0.5 mL of Adjuvant
System. The 10 mg dose was prepared by mixing five vials of
AS01B with one vial of FMP2.1 antigen and withdrawing 0.5 mL
for sterile injection. The adjuvant and antigen were stored at 2–8u
Celsius. On vaccination days, the vials were placed on wet ice no
longer than 4 hours, and the vaccine formulated immediately
prior to injection. The vaccine constituents have undergone
extensive stability testing and have been show to be stable for up to
24 hours at room temperature. For clarity, the FMP2.1 vaccine
antigen herein will be referred to as AMA-1 in this publication.
This was a first-in-human study of AMA-1/AS01B; therefore, a
3-week staggered dosing schedule of this formulation was
incorporated into the study design. In the open-label phase of
the study, 5 volunteers received 10 mg AMA-1 in 0.5 mL of
AS01B (referred to as the low dose AMA-1/AS01B group)
administered intramuscularly in the non-dominant arm. A Safety
Monitoring Committee (SMC) reviewed the safety data accumu-
lated during the four days following the first immunization and
recommended commencing immunizations with the higher dose
of AMA-1. Thirty volunteers were assigned in a double-blind,
randomized fashion to receive either 50 mg of AMA-1 in 0.5 mL
of AS01B (referred to as the full dose AMA-1/AS01B group) or
50 mg AMA-1 in 0.5 mL of AS02A (referred to as the full dose
AMA-1/AS02A group). A total of three immunizations were given
at one-month intervals, all administered intramuscularly in
alternate arms. The blinding code was broken after completion
of the efficacy phase.
Objectives
The primary objective of this trial was to assess the safety and
reactogenicity of candidate malaria vaccines FMP2.1/AS01B and
FMP2.1/AS02A when administered intramuscularly on a 0-, 1-,
and 2-month (0-, 28- and 56-days) immunization schedule to
malaria-naı ¨ve adult volunteers living in the United States.
Secondary objectives were to assess the magnitude of humoral
immune responses induced by the candidate malaria vaccines, the
functionality of these anti-FMP2.1 antibodies to inhibit the growth
of asexual parasites and to assess the efficacy of the vaccine
candidates against sporozoite challenge with P. falciparum. The
tertiary objective of the study was to assess the cell-mediated
immune responses to FMP2.1/AS01B and FMP2.1/AS02A.
Outcomes
To evaluate the primary objective of safety and reactogenicity of
AMA-1/AS01B and AMA-1/AS02A, after each immunization,
the occurrence of solicited symptoms over a 7-day follow-up
period and unsolicited symptoms over a 30-day follow-up period,
as well as any serious adverse events (SAEs) during the study
period were collected. Solicited symptoms included local adverse
events (pain, erythema and swelling) and systemic adverse events
(fever, nausea, headache, malaise, myalgia, fatigue, and arthral-
gia). All symptoms were graded on a scale to indicate degree of
functional impairment (Grade 0: no impairment, Grade 1: easily
tolerated, Grade 2: interferes with daily activity, Grade 3: prevents
daily activity) except for injection site erythema and swelling,
which were graded as a physical measurement taken at the
greatest diameter of involvement (Grade 0: 0 mm, Grade 1: $1–
#20 mm, Grade 2: .20–#50 mm, Grade 3: $ 50 mm), and
fever, which was graded on the following scale of oral temperature:
Grade 0: #37.5uC, Grade 1: .37.5–#38uC, Grade 2: .38–
#39uC, Grade 3: .39uC. Hematologic and biochemical tests for
safety were collected on Days 0, 14, 28, 42, 56 and 70, and again
at three months after challenge for those volunteers enrolled in the
efficacy phase.
The secondary objectives were twofold: to assess vaccine
immunogenicity and determine vaccine efficacy. Immunogenicity
endpoints included anti-AMA-1 antibody titers as determined by
Enzyme-Linked Immunoassay (ELISA), as well as functionality of
anti-AMA-1 antibodies versus blood stage P. falciparum parasites as
measured by standardized homologous (3D7 allele) and heterol-
ogous (FVO allele) growth inhibition assay (GIA).
Enzyme-Linked Immunoassay. Serum for anti-AMA-1
antibody determination was collected from each volunteer at
Day 0, 14, 28, 42, 56, 70, 93, 114 and 156 and frozen at 220uCo r
below until tested as described previously [16]. The AMA-1 plate
antigen was prepared from the same bulk FMP2.1 vaccine antigen
lot as the test article. ELISA titers, initially defined as the serum
dilution yielding an optical density of 1.0 in a standardized assay,
were converted to mg/ml concentration values. As was done for a
previous ELISA [25], commercially obtainable human IgG was
utilized to develop an IgG-quantitation sandwich ELISA. Using
this ELISA, the concentration of anti-AMA-1 antibody was
determined for a single control serum sample. Each sample tested
was then analyzed against this control (run on each test sample
plate) to generate a normalized mg/ml value. The resulting data
are summarized by vaccine group as Geometric mean
Concentration (GMCs) with 95% confidence intervals (CIs).
Growth-Inhibition Assay. Serum samples were pre-absorbed
with 5 ml of human red blood cells (RBC), at 50% hematocrit, per
100 ml of serum for 1 hour and tested at 20% for growth inhibition
by measuring parasite lactate dehydrogenase (pLDH) activity [26].
Parasitized RBC (pRBC) cultures of both the 3D7 allele
(homologous) and FVO allele (heterologous) at the early schizont
stage were set up with pre-immune and immune sera at various
concentrations at a 0.3% parasitemia and 1% hematocrit. Assay
plates were sealed in bags containing 2.5% CO2, 2.5% O2, 90% N2
and incubated for 40 or 48 hours (cycle time of 3D7 and FVO
parasites respectively). Cultures were then harvested by transferring
50 ml/well into phosphate buffered saline (PBS)-containing C-
bottom plates and washed by spinning plates for 10 minutes at
10,000 g. Once completed, plates were frozen at 230uC until
analysis. To measure the amount of pLDH activity, a substrate
buffer containing 0.1 M Tris HCl, 50 mM Sodium-L-lactate, 0.255
Triton-X, 10 mg NBT, 10 mg/ml 3-Acetylpyridine, 10 U/ml
diaphorase from Clostridium klyiveri (all reagents were obtained
from Sigma, St. Louis, MO) was added to the plates. Colorimetric
measurement at 650 nm was done after 30 minutes of reaction time
using the SpectraMax Plus 384 spectrophotometer (Molecular
Devices, Sunnyvale, CA). Pre-vaccination samples were run in
parallelwiththe post vaccination samples,andcalculation ofgrowth
inhibition was determined by using the formula: %
inhibition=[12[(OD immune serum2OD RBC)/(OD pre-
immune serum2OD RBC)]]6100. Volunteers demonstrating
$20% activity were considered responders, a reproducible cut-off
value calculated based on mean inhibition of pre-immune sera+2
standard deviations. This cut-off value is the threshold for serum
antibody-specific inhibition over the determined assay background
levels (which vary between individuals) and can be caused by
nutritional differences and handling artifacts of the sera [26].
GIAs were also performed in parallel at the GIA Reference
Center at the National Institutes of Health by Dr. Carole Long.
Performing both methods provided an opportunity to provide
comparability and bridging information regarding the inhibitory
antibody responses obtained by the two assays. The NIH assay
similarly measures inhibition of pLDH activity of both 3D7 and
FVO alleles of P. falciparum [26]; however, a purified immuno-
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compared to 20% diluted serum [27]. Results in this manuscript
are reported for an immunoglobulin concentration of 4 mg/mL
for Day 70 serum samples using the same equation for calculation
of percent inhibition.
Efficacy. Efficacy was measured as development of
parasitemia and time to parasitemia after malaria challenge as
determined by light microscopy. Approximately two weeks after
completion of all three immunizations (Day 70), volunteers from
the high dose vaccine groups underwent homologous sporozoite
challenge. Six healthy, malaria-naive adults aged 18 to 50 years
were also enrolled as non-immunized infectivity controls. The
sporozoite challenge was conducted as described previously
[21,28]. Volunteers were monitored closely with daily visits and
blood smears starting five days after challenge. Two hundred high-
powered fields were examined on each blood film to detect patent
parasitemia. This number was increased to 1000 fields if the
volunteer became symptomatic, and in the case of persistent
symptoms, additional fresh blood smears were prepared and read
at 6- to 8-hour intervals. Once a volunteer was found to be
parasitemic, a directly observed oral regimen of chloroquine was
administered, and three consecutive negative daily blood smears
were taken to ensure parasite clearance. Thereafter, weekly blood
smears were prepared over the next 4-week period. Vaccine
efficacy (VE) was defined as VE=incidence in unvaccinated
(Iunvac)2Ivac/Iunvac).
Additional endpoints included determination of cell-mediated
immune responses by IFN-c ELISPOT assays and quantification
of peripheral parasitemia by quantitative PCR (qPCR).
IFN-gamma Enzyme-linked Immunospot assay (IFN-c
ELISPOT). Peripheral blood mononuclear cells (PBMCs) from
peripheral blood were isolated and ex vivo IFN-c ELISPOT assays
performed as described in the initial Phase 1 AMA-1/AS02A study
previously conducted at WRAIR [16]. Briefly, cryopreserved
PBMCs were cultured for 24 hours in triplicate wells in a 96-well
culture plate at 200,000 PBMCs per well in the presence of three
concentrations of FMP2.1 (0.1 mg/mL, 1 mg/mL or 10 mg/mL) or
medium control. At the conclusion of this step, which acts to
decrease non-specific and/or background responses, the PBMCs
were transferred to a multi-screen 96-well filtration ELISPOT plate
(Millipore Corporation, Bedford, MA) pre-coated with mouse anti-
human monoclonal antibody, 1-DIK, (MabTech, Sweden) and
cultured for another 18 hours. The PBMCs were decanted and
plates washed with PBS, with subsequent addition of a biotinylated
anti-IFN-c antibody (MabTech AB, Sweden). The assay was
developed using alkaline phosphatase-streptavidin (MabTech AB,
Sweden) with addition of substrate (Bio-Rad, Hercules, CA). The
spots were counted using an IPLab analyzer (Scan-analytics,
Fairfax, VA) and the results were expressed as the mean of the
triplicate wells’ spot forming units (sfu) per 10
6 PBMCs.
Quantitative PCR. Two mL blood samples were collected in
EDTA tubes on the morning of the Day of Challenge (DOC) and
then daily starting five days after challenge until the volunteer
became parasitemic as detected by blood film. Briefly, the blood
sample was passed through a leukofilter (24-well filter plate with
vacuum manifold, Whatman, Clifton, NJ) to remove human
leukocytes, washed three times with PBS and the DNA extracted
from a 500 ml sample using a Qiagen miniprep kit (Qiagen,
Valencia, CA) [29]. The PCR reaction [30] amplified the 18S
ribosomal RNA gene of P. falciparum. Primers and probe are as
follows: Forward- 59-GTA ATT GGA ATG ATAGGA ATTTAC
AAG GT-39, Reverse- 59-TCA-ACT-ACG-AAC-GTT-TTA-
ACT-GCA-AC-39, Taqman probe- TGC-CAG-CAG-CCG-
CGG-TAA-TTC (FAM and TAMRA labeled). Reaction contents
totaled 25 ml and included 1 ml DNA template, 300 nM of each
primer and 200 nM probe with 250 mM of each deoxynucleotide,
0.125 U Amplitaq Gold polymerase, 5 mM MgCl2,a n d1 6
Taqman buffer. Cycling conditions were 15 minutes denaturing
andactivationat95uCfollowedbyamplification cycleof15 seconds
at 95uC, and 1 minute at 60uC for 45 cycles and conducted in the
Opticon 2 machine (Biorad, Hercules, CA). Standards of known P.
falciparum concentrations were made at dilutions from human blood
at 3% parasitemia of 2610
6,2 610
5,6 610
4,2 610
4,6 610
3,2 610
3,
200, and 20 parasites per ml blood using SYBR Green dye and BD
FacsCaliber (San Jose, CA) to enable construction of a standard
curve. A whole blood sample containing no parasites was included
as a negative control. Blood samples were filtered using the multi-
well filter plates, and the DNA was extracted. A standard curve was
produced based on the mean of data points from five independent
experiments. The threshold cycle (Ct) was defined as the cycle at
which the fluorescence of the samples crossed two standard
deviations above the mean background fluorescence of the
negative (uninfected human blood DNA). The standard curve R
squared value was 0.994 and results were expressed as parasites per
mL. A previously described statistical model [31] was used to
estimate (1)reductionof growth rate (beta2), and (2)reductionof the
number of infected hepatocytes (X) per volunteer. Because of the
limited number of qPCR data points, growth rates (with 95% CIs)
were estimated per immunization group, and the parameters of
duration of parasitemia and prepatent period fixed with their
respective variance (b1, m1,2,3 and s1,2,3 ) according to values from
the previous study [31].
Sample Size
The group sizes were designed to mirror previous Phase 1 and
Phase 2a malaria vaccine challenge studies performed using the
WRAIR challenge model. The logistics of the challenge model
limits the total number of volunteers challenged with malaria. The
study has 80% power to detect a prolongation in the prepatent
period of approximately two days in immunized volunteers as
compared with controls. This study was designed to assess safety,
immunogenicity, and efficacy of two candidate vaccines and not
for the support of vaccine intergroup comparisons.
Randomization
The five volunteers who received the low dose of AMA-1/
AS01B were not randomized nor blinded to the vaccine
administered in order to conduct the appropriate safety evaluation
of this vaccine formulation prior to proceeding with a higher dose
formulation. For volunteers receiving the full dose of vaccine, prior
to the day of first immunization, a computerized randomization
list was generated by Statistics Collaborative, Inc. assigning
volunteers a randomization code number to uniquely identify
the group to which the volunteer belonged. The set of individual
randomization code numbers was kept in code break envelopes by
the medical monitor.
Blinding
As the adjuvants were different in presentation (vials versus pre-
filled syringes), specific steps were implemented to insure that
vaccines were administered and evaluated in a double-blind
manner. An Immunization Team was created consisting of one
physician and one study coordinator and was responsible for
maintaining the blind during vaccine preparation and adminis-
tration. These team members were not involved in the clinical
evaluation of vaccine safety and reactogenicity during the
Immunization Phase. At the conclusion of the malaria challenge,
the unbroken code envelope was given by the medical monitor to
Phase 1/2a AMA-1 Vaccine Trial
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analysis. Safety data analysis was performed by Statistics
Collaborative, Inc after the last study visit had concluded.
Immunogenicity data was not unblinded to sub-investigators until
after all endpoint assays were complete.
Statistics
Study data for demographics, solicited and unsolicited adverse
events, and clinical laboratory tests for all enrolled volunteers who
received at least one immunization, as well as efficacy as
determined by light microscopy, were entered into a database,
queried, verified and locked prior to analysis. For ELISA data, all
titers were log-transformed and analysis of variance (ANOVA) was
used to assess the difference between vaccine groups at baseline,
with a repeat measure ANOVA to evaluate the effect of the
vaccine on longitudinal data from day 14 post-immunization. For
GIA and ELISPOT data, statistical analysis by ANOVA was used,
and for PCR results were expressed as day of patency or parasites/
mL and compared by Kaplan Meier survival curve (log rank test)
or repeat measures ANOVA (log transformed) and Student’s t-test
respectively. Tukey’s Test was used for all post-hoc pairwise
comparisons. Analysis for comparisons among endpoints and
prepatent periods used Spearman correlation or Mann-Whitney
tests and were done with GraphPad Prism software 4.0. All other
analyses were implemented using SAS 9.1.3 software. All statistical
tests were two-sided with an alpha of 0.05.
Results
Participant Flow
As shown in the study flow diagram (Figure 1), 98 adults
underwent screening. Of these, 47 were eligible, 35 were enrolled
as vaccinees, and 6 were enrolled as infectivity controls. The
recruitment period began September 11, 2006, was completed for
vaccinees at the end of October 2006, and a second brief
recruitment period for infectivity controls occurred during the
month of January 2007.
Baseline data
The demographic make-up of the enrolled volunteers is shown
in Table 1 and was similar in ethnicity, sex and age among the
vaccine groups and the infectivity controls. The percentage of
military personnel enrolled in the study was 29%. Five volunteers
were enrolled in the low dose group while 15 volunteers received
full dose AMA-1/AS01B and 15 volunteers received full dose
AMA-1/AS02A. Thirty-three of 35 vaccinees received all three
scheduled vaccinations; one volunteer (full dose AMA-1/AS02A
recipient) withdrew due to a scheduling conflict, and another
volunteer (full dose AMA-1/AS01B recipient) was withdrawn due
to a clinical adverse event - a rash thought to be related to vaccine
administration (see below). Of 27 vaccinees eligible for malaria
challenge, 16 elected to undergo malaria challenge along with 6
unimmunized infectivity controls. The numbers analyzed for
safety and immunogenicity included those volunteers meeting all
Figure 1. Participant flow diagram.
doi:10.1371/journal.pone.0005254.g001
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protocol, and for whom results were available after receiving at
least one study vaccination. For efficacy results, only volunteers
who underwent primary challenge were included.
Outcomes and Estimation
Safety. A summary of solicited post-immunization adverse
events (AEs) recorded in each 7-day follow-up period is presented
in Table 2. Local injection site events were common and similar in
prevalence among the three vaccine groups. Erythema and
swelling increased in frequency and intensity with subsequent
immunizations, with most (79–100%) volunteers in all groups
experiencing Grade 3 swelling after the third vaccination. The
erythema and swelling were not accompanied by significant
functional impairment, and no Grade 3 injection site pain was
reported.
The most common systemic adverse events in all three groups of
immunized volunteers were headache, malaise, and fatigue. An
increase in frequency and intensity of systemic adverse events in
the second and third immunizations as compared to the first was
also noted. Over the course of three immunizations, only 8 of 315
(3%) of solicited systemic events were rated Grade 3, and these
occurred in five volunteers (14% of volunteers); all were
immunized with full dose AMA-1/AS01B. Of these five
volunteers, three reported systemic events after the second
immunization and two after the third immunization. These few
systemic Grade 3 events, as well as all other local and systemic
adverse events, were short-lived, with 87% of all events occurring
and resolving within the first 72 hours after immunization.
The number of volunteers experiencing any solicited AE, local
or systemic, after each immunization was similar in the three
groups (data not shown, Fishers exact test, p=1.0), except after the
first immunization, when the number of volunteers immunized
with full dose AMA-1/AS01B experiencing at least one systemic
adverse event was greater than those volunteers receiving full dose
AMA-1/AS02A (11/15 volunteers versus 4/15 volunteers,
respectively, Fishers exact test, p=0.027). While the small number
of volunteers limits statistical comparisons between each solicited
adverse event at each immunization time point, the frequency of
each solicited adverse event appeared comparable in all groups.
No SAEs or clinically significant vaccine-related laboratory test
abnormalities occurred during the execution of the study.
One unexpected adverse event did occur in a volunteer 18 days
after receiving the second immunization with full dose AMA-1/
AS01B. An erythematous, papular, slightly pruritic rash appeared
intermittently over both deltoid areas, (corresponding to the two
previous injection sites) during a 2-week period. There were no
other associated local or systemic symptoms, and no therapeutic
medications were required or administered. Hematologic and
biochemical safety laboratory tests performed at the time were
normal, and a biopsy of the site by a dermatologist revealed non-
specific, chronic inflammation. The volunteer was withdrawn from
the study and, over the next six months, the rash recurred three
times without apparent provocation and eventually resolved
without sequelae.
Immunogenicity-ELISA. Figure 2 shows the group GMCs
of anti-AMA-1 antibodies as determined by antibody ELISA at
specified time points during the study. Seroconversion, defined as
concentrations .2 standard deviations (SD) above the group
GMC at baseline, occurred in 100% of volunteers after second
immunization, with peak GMC of antibody increasing at least
200-fold in all three vaccine groups. Two weeks post-third
vaccination, anti-AMA-1 GMCs and 95% CIs were: low dose
AMA-1/AS01B 196 mg/mL (103–371 mg/mL), full dose AMA-1/
AS01B 279 mg/mL (210–369 mg/mL) and full dose AMA-1/
AS02A 216 mg/mL (169–276 mg/mL). Among the three vaccine
groups, there was no significant difference in antibody
concentrations by longitudinal analysis (p=0.55, repeated
measures ANOVA) or by point-wise comparison with the
exception of Day 42 when full dose AMA-1/AS01B induced
higher concentrations than low and full dose AMA-1/AS02A (data
not shown). While there was boosting with the third
immunization, the maximum concentrations measured were not
significantly higher than concentrations reached after second
immunization for any vaccine group. Three months after the third
immunization, antibody concentrations in those volunteers who
underwent sporozoite challenge in both vaccine groups remained
significantly greater than controls with an approximate half–life of
approximately 52 days, similar to the half-lives seen over the post-
vaccination period in malaria-naı ¨ve adults administered three
doses of adjuvanted recombinant protein vaccine [16,32].
Immunogenicity-GIA. There was demonstrable growth
inhibition by anti-AMA-1 antibodies at two weeks post-third
immunization (Day 70/DOC) as measured by 20% serum GIA
performed at WRAIR using homologous 3D7 parasites. In the low
dose AMA-1/AS01B group, 60% (3 of 5) of volunteers were
responders, while in the full dose AMA-1/AS01B group, 79% (11
of 14) and the full dose AMA-1/AS02A group, 86% (12 of 14) of
Table 1. Study volunteer demographics.
10 mg AMA-1 in AS01B
(n=5)
50 mg AMA-1 in AS01B
(n=15)
50 mg AMA-1 in AS02A
(n=15)
Infectivity Controls
(n=6) Overall (n=41)
Sex, n (%)
Male 3 (60) 7 (47) 8 (53) 2 (33) 20 (49)
Female 2 (40) 8 (53) 7 (47) 4 (67) 21 (51)
Age, years Mean (SD) 30.2 (10.5) 29.7 (6.0) 30.2 (8.7) 24.5 (7.7) 29.2 (7.8)
Ethnicity/race, n (%)
White 2 (40) 10 (67) 13 (87) 5 (83) 30 (73)
African-American 2 (40) 3 (20) 0 1 (17) 6 (15)
Hispanic or Latino 1 (20) 1 (7) 1 (7) 0 3 (7)
Asian 0 1 (7) 0 0 1 (2)
Middle Eastern 001 ( 7 ) 0 1 (2)
doi:10.1371/journal.pone.0005254.t001
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percent growth inhibitory activity among all three groups was not
significantly different: 23%, 32%, and 30% respectively (p=0.22,
one-way ANOVA). Inhibitory activity of all serum samples against
heterologous FVO parasites was below the responder cut-off level
of 20% (data not shown).
Assays performed at the GIA Reference Center at NIH with
purified immunoglobulin also found similar mean percent
inhibitions among the 3 vaccine groups (Figure 3b): low dose
AMA-1/AS01B 61% inhibition, full dose AMA-1/AS01B 77%
inhibition, full dose AMA-1/AS02A 70% inhibition, (p=0.11,
one-way ANOVA). The inhibitory activity was again limited to
homologous 3D7 parasites, with no significant inhibition against
FVO parasites demonstrated (data not shown). These two GIA
methodologies, one using 20% serum and the other purified
immunoglobulin, correlated well (Pearson’s Correlation Coeffi-
cient r=0.76, p,0.0001). As previously shown [16], the present
study again demonstrated a good correlation of the anti-AMA-1
inhibitory activity, as measured by the WRAIR GIA, to WRAIR
ELISA results (Spearman correlation coefficient r=0.82,
p,0.0001). In addition, NIH GIA results correlated well with
WRAIR ELISA (Spearman correlation coefficient r=0.77,
p,0.0001) as well as NIH ELISA results (Spearman correlation
coefficient r=0.9, p,0.0001).
Immunogenicity-ELISPOT. Ex vivo IFN-c ELISPOT assays
were performed using the PBMCs of volunteers at baseline, Day
70/DOC and three months post-challenge as shown in Figure 4
and expressed as mean sfu per million PBMCs. Baseline responses
for each vaccine group were as follows: low dose AMA-1/
AS01B=14, full dose AMA-1/AS01B=2 and full dose AMA-1/
AS02A=6. There was a demonstrable increase in IFN-c
production after the third immunization in all vaccine groups.
Those volunteers immunized with low dose vaccine had greater
production of IFN-c at Day 70 as compared to the volunteers
immunized with full dose AMA-1/AS01B or full dose AMA-1/
AS02A (low dose AMA-1/AS01B=877, full dose AMA-1/
Table 2. Local and systemic solicited adverse events (AEs) Day 0 through Day 7.
Vaccine AE Imm #1I m m # 2I m m #3
% (%G3) % (%G3) % (%G3)
10 mg AMA-1/AS01B Local Pain 80 (0) 80 (0) 60 (0)
n=5 Erythema 0 (0) 60 (40) 80 (60)
Swelling 20 (0) 80 (60) 80 (80)
Systemic Fever 20 (0) 40 (0) 20 (0)
Nausea 20 (0) 20 (0) 20 (0)
Headache 40 (0) 40 (0) 60 (0)
Malaise 20 (0) 80 (0) 60 (0)
Myalgia 0 (0) 60 (0) 0 (0)
Fatigue 20 (0) 60 (0) 80 (0)
Joint Pain 0 (0) 20 (0) 20 (0)
50 mg AMA-1/AS01B Local Pain 100 (0) 93 (0) 93 (0)
n=15* Erythema 27 (13) 73 (27) 79 (57)
Swelling 67 (47) 80 (47) 100 (100)
Systemic Fever 27 (0) 53 (7) 36 (0)
Nausea 7 (0) 47 (0) 29 (7)
Headache 33 (0) 60 (0) 57 (0)
Malaise 33 (0) 73 (7) 64 (7)
Myalgia 20 (0) 60 (7) 43 (0)
Fatigue 40 (0) 67 (7) 57 (7)
Joint Pain 20 (0) 33 (0) 14 (7)
50 mg AMA-1/AS02A Local Pain 93 (0) 93 (0) 86 (0)
n=15* Erythema 33 (0) 40 (33) 86 (57)
Swelling 73 (33) 93 (67) 93 (79)
Systemic Fever 7 (0) 27 (0) 21 (0)
Nausea 0 (0) 20 (0) 7 (0)
Headache 27 (0) 47 (0) 43 (0)
Malaise 13 (0) 40 (0) 43 (0)
Myalgia 7 (0) 47 (0) 36 (0)
Fatigue 13 (0) 53 (0) 43 (0)
Joint Pain 0 (0) 0 (0) 0 (0)
Organized by AMA-1 dose and Adjuvant Group, AEs solicited post immunization with highest grade reported. Reported by percentage experiencing AE, with percent
experiencing Grade 3 in parentheses. Imm=Immunization, G3=Grade 3. * For third immunization n=14.
doi:10.1371/journal.pone.0005254.t002
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ANOVA, p,0.001 post-test Tukey’s for low dose AMA-1 versus
either high dose vaccine). There was no statistical difference in
IFN-c production between volunteers immunized with full dose
AMA-1/AS01B or full dose AMA-1/AS02A at any time point.
Efficacy. All 22 volunteers, 16 vaccinees and 6 controls,
became parasitemic as determined by blood smear between 9 and
12 days after sporozoite challenge (Figure 5a), corresponding to a
vaccine efficacy (VE) of 0%. There was also no difference in the
mean prepatent periods as measured by light microscopy.
The prepatent period was also determined using qPCR from P.
falciparum DNA isolated from peripheral blood drawn every
morning (Figure 5b). The detection of parasitemia by PCR
occurred approximately two days earlier than by blood film. On
Day 7 post-challenge, all six infectivity controls became PCR
positive, while four of six volunteers immunized with full dose
AMA-1/AS01B and six of ten volunteers immunized with full dose
AMA-1/AS02A did so; however, these differences are not
statistically significant.
To further explore whether the high dose vaccines had an effect
on parasite development in the liver or growth rate in the blood or
both, we examined level of parasitemia from Day 7 (first parasite
detection by PCR) up to and including Day 12 by qPCR. Among
the three groups (two full dose vaccine groups and infectivity
control group), there was a strong, statistically significant
difference in longitudinal measurement of peripheral parasitemia
on Days 7–9, the days in which peripheral parasitemia was
detected and measured by qPCR and no treatment with
chloroquine had yet been initiated (p=0.0002, repeated measures
ANOVA, data not shown). Post-test analysis showed significantly
lower parasitemia in volunteers receiving full dose AMA-1/AS02A
(Tukey’s Test, p ,0.0001), as well as a trend toward lower parasite
Figure 2. Geometric mean concentration (GMC) of anti-AMA-1 antibody by ELISA. Arrows indicate immunization time points and
arrowhead indicates day of malaria challenge. Gray solid line with & symbol: GMCs for low dose AMA-1/AS01B vaccinees; black solid line with
msymbol: GMCs for high dose AMA-1/AS02A vaccinees; small black dashed line with $ symbol: GMCs for high AMA-1/AS01B vaccinee;, small dashed
gray line with ¤symbol: GMCs for infectivity controls. 95% CIs are shown for each time point.
doi:10.1371/journal.pone.0005254.g002
Figure 3. Mean percent growth inhibition activity of 3D7 parasites by GIA. (A) WRAIR 20% serum pLDH GIA (B) NIH pLDH GIA at 4 mg/mL
purified immunoglobulin. Results expressed as mean percent inhibition with serum from Day 70 using GIA methods described in Outcomes section.
Low dose AMA-1/AS01B (n=5), full dose AMA-1 in AS01B or AS02A (n=14 in each).
doi:10.1371/journal.pone.0005254.g003
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Test, p=0.084) as compared to controls.
Figure 6 shows the data points and the fit of parasitemia of the
three groups. The estimated growth rates with 95% CIs of the
AMA-1/AS01B group (14.5, 9.8–21.6) and AMA-1/AS02A group
(13.9, 8.6–23.5) were slightly lower but not statistically different
from the control group (16.8, 10.5–26.8). However, the number of
infected hepatocytes and/or the first wave of RBC invasion of the
AMA-1/AS02A group (24.6 6 33.0) was significantly lower
(p=0.044, t-test) as compared to the control group (171 6 135).
AMA-1/AS01B also showed a lower first wave (73.6 6 68.7), but
this difference was not significant (p=0.146, t-test).
Efficacy by immunological endpoint. We did examine the
relationships between immunological endpoints and prepatent
periods as determined by light microscopy and by qPCR for each
challenged volunteer. No correlation was demonstrated between
prepatent period and ELISA titer, percent inhibition by serum
GIA, or cellular IFN-c production by ELISPOT (data not shown).
In further post-hoc analyses, the 4 volunteers with the longest
prepatent periods by qPCR did not have significant differences in
Figure 4. Comparison of IFN-c ELISPOT results. Results expressed as mean sfu/million PBMCs with standard error bars. Low dose AMA-1/AS01B
(n=5), full dose AMA-1 in AS01B or AS02A (n=14 in each). For Day 156, includes only challenged volunteers. Recombinant protein AMA-1
concentration 1.0 mg/mL. Assay also run at 0.1 mg/mL and 10 mg/mL with similar results (data not shown).
doi:10.1371/journal.pone.0005254.g004
Figure 5. Kaplan-Meier (K-M) Survival Curve for prepatent period. Legend: — Full dose AMA-1/AS01B
…… Full dose AMA-1/AS02A – – –
Infectivity Controls. (A) Prepatent period by thick blood film. Mean prepatent periods: full dose AMA-1/AS01B 10 days (240 hours), full dose AMA-1/
AS02A 10 days 21 hours (261 hours), infectivity controls 10 days (240 hours), K-M survival curve log rank 2.94, P=0.23. (B) Prepatent period by qPCR.
Mean prepatent periods: full dose AMA-1/AS01B 7 days 12 hours (180 hours), full dose AMA-1/AS02A 7 days 17 hours (185 hours), infectivity controls
7 days (168 hours), K-M survival curve log rank 3.25, P=0.19.
doi:10.1371/journal.pone.0005254.g005
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In addition, the immunogenicity results obtained by ELISA, GIA
and ELISPOT were not significantly different between those
volunteers that underwent challenge and those who did not (data
not shown).
Discussion
In this paper, we describe the first safety, immunogenicity and
efficacy trial for a recombinant AMA-1 antigen formulated with
either AS01B or AS02A.
Interpretation
All three vaccine candidates, low dose AMA-1/AS01B, full dose
AMA-1/AS01B and full dose AMA-1/AS02A, had a good
tolerability profile but caused moderate reactogenicity, manifested
specifically by local erythema and swelling. There was no
difference in frequency or pattern of local adverse events among
the three vaccine groups; although it did appear that the
volunteers administered the full dose AMA-1/AS01B experienced
slightly more systemic adverse events. For all three groups, there
was an increase in frequency and intensity of adverse events with
successive immunizations, yet the adverse events did not
contribute to volunteer attrition as evidenced by completion of
103 of 105 scheduled vaccinations in 35 subjects. The frequency of
adverse events described here is greater (for all three groups) than
that described in recent trial of AMA-1/AS02A [16], and RTS,S
in AS02A [28,32,33] or AS01B (personal communication, K.
Kester) in malaria-naı ¨ve adults at WRAIR; however, Grade 3
swelling, accompanied by little or no pain, similar to that seen in
this study, was consistently reported in Malian adults [17] and
children vaccinated with AMA-1/AS02A (personal communica-
tion C. Plowe). The reason for the increased local and systemic
reactogenicity in this study is unclear but may be due to an
intrinsic immunologic property of adjuvanted recombinant AMA-
1. It is likely not due to endotoxin or residual bacterial host
contaminant given the strict cGMP standards of AMA-1 and
Adjuvant Systems manufacture. A recent Phase 1a study of Pichia
pastoris-expressed AMA1 formulated in AS02A also had elevated
frequency of mild to moderate pain, erythema and systemic
adverse events reported [34].
The unexpected adverse event seen in one volunteer was
considered related to the vaccine given its consistent localization
over both injection sites. Based on the timing of rash onset, this
reaction could have represented either a Type IV hypersensitivity
reaction or possibly antigen-antibody complex formation without
accompanying systemic symptoms of serum sickness [35]. When
evaluated, the anti-AMA-1 antibody levels and IFN-c ELISPOT
responses in this individual were not markedly elevated or
depressed as compared to other volunteers in the study.
Immunization with all three vaccine formulations produced
very high antibody titers in the majority of volunteers, with no
statistically significant difference in GMCs among vaccine groups.
Our findings are consistent with preclinical data that malarial
recombinant protein antigens elicit equivalent (or greater)
antibodies when formulated with AS01B versus AS02A [18–20]
and Phase 1a vaccine studies in which antibody titers did not differ
by the dose of AMA-1 formulated in AS02A [16,34]. The third
immunization did provide a boost to falling antibody titers,
although the peak level measured was not significantly higher than
the peak achieved post-second immunization, a finding also seen
in the recent Phase 1a study of AMA-1/AS02A at WRAIR [16].
This finding raises the question of whether an effective
immunization regimen can be limited to two immunizations, or
alternatively, how the time interval between second and third
immunization could be optimized.
The growth inhibition of homologous 3D7 P. falciparum parasites
was the highest yet reported for any immune serum or purified
antibody GIA assessed in Phase 1a trials of blood stage malaria
vaccines [16,34,36–39]. Although the vaccine did induce a
humoral response demonstrating in vitro GIA activity, the absence
of protective efficacy suggests that GIA may not serve as an
accurate correlate of protection. In addition, the inhibitory
responses induced by this allele of AMA-1 were highly strain-
Figure 6. In-vivo growth of blood stage parasites after P. falciparum challenge. Observed parasite densities of individuals (dots) and
predicted kinetics (as a group, thick continuous line) in the three immunization groups experimentally infected with Plasmodium falciparum (3D7).
Dots represent observed number of parasites per milliliter of blood based on qPCR results. Individuals in the same group are represented in the same
color (Infectivity Controls: black (n=6), Full dose AMA-1/ASO1B: red (n=6), Full dose AMA-1/ASO2A: blue (n=10)). All data points represent
pretreatment parasitemias.
doi:10.1371/journal.pone.0005254.g006
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FVO parasites similar to findings observed in other studies, both
preclinical [8] and clinical [16,27].
All three vaccine candidates induced cellular responses as
measured by IFN-c production. Interestingly, the volunteers
receiving the 10 mg dose of AMA-1/AS01B had significantly
higher responses to recombinant protein antigen than the
volunteers receiving the 50 mg dose of AMA-1 in either Adjuvant
System. This phenomenon of a greater T-cell response with a
reduced antigen dose (as compared to full dose) but constant
amount of adjuvant was also seen in a recent trial of Liver Stage
Antigen-1 (LSA-1) (manuscript in press, J. Cummings) as well as in
the Phase 1b study of AMA-1/AS02A in Malian adults (manuscript
in revision, K. Lyke). It has been reported in Phase 2a challenge
trials of RTS,S/AS02A [32,40], RTS,S/AS01B (personal com-
munication, K. Kester) and heterologous prime-boost immuniza-
tion regimens with antigen based on thrombospondin-related
adhesion protein (TRAP) [41,42] that elevated antigen-specific
IFN-c responses are associated with a delay in the prepatent
period and protection against parasitemia. However, this associ-
ation has yet to be demonstrated in a malaria-experienced
population. In addition there may be a cellular versus humoral
tradeoff: in a recent trial in Malian adults, there was a trend
towards greater antibody responses in subjects who received 50 mg
AMA-1 formulated in AS02A as compared to 25 mg AMA-1/
AS02A [17].
This was the first clinical trial of any AMA-1-based vaccine
using the rigorous sporozoite challenge model in order to assess
efficacy. The challenge model traditionally used to assess efficacy
of pre-erythrocytic vaccine candidates is robust: at WRAIR, a
100% infection rate has been obtained in the last 100 infectivity
control volunteers fed upon by 5 Anopheline mosquitoes which were
each highly infected with P. falciparum sporozoites. In addition, the
clinical protocol under which the subjects are challenged requires
malaria treatment without delay upon diagnosis of parasitemia by
light microscopy, thus precluding subsequent direct observation of
any parasitemia-limiting effects or abrogation of clinical manifes-
tations that may be induced by a blood stage vaccine. Under these
stringent conditions, there was no prevention of parasitemia or
delay in the onset of parasitemia by light microscopy. A sensitive,
quantitative PCR analysis also did not reveal any statistically
significant delay in the time to parasitemia in vaccinees versus
infectivity controls.
We conducted exploratory post hoc analyses to detect more
subtle signs of a vaccine effect that we hypothesized could be
reflected by a reduction or impairment of released hepatic
merozoites and/or a reduction in parasite growth rate in the
blood stage. Analysis showed that the first peak (representing the
first wave of RBC invasion and/or the number of infected
hepatocytes per volunteer) in the AMA-1/AS02A vaccinees was
about 7 times lower compared to the control group (figure 6).
AMA-1/AS01B showed a mean reduction of about 50%, but this
was not significant. Unfortunately, due to the limited number of
qPCR data points restricted by the once daily measurements, the
power of the statistical model is reduced. The inhibitory antibodies
induced by AMA-1/AS02A may act at 2 different levels: reduction
of sporozoite invasion into the hepatocytes as observed in-vitro [7]
and/or a reduction of the first wave of liver merozoites invading
new red blood cells. The estimated mean reduction of 17% in
growth rate is too small to effectively reduce parasite multiplica-
tion. It has been estimated that in vivo growth inhibition needs to
be at least 70% to realize a decrease in parasitemia [31].
With the current challenge model and need to treat individuals
upon first detection of parasitemia, it is not possible to ascertain
the potential benefit or duration of this observed reduction in
parasite burden. Additional post hoc analyses comparing vaccinees
with prepatent periods revealed no correlation with antibody titer
by ELISA, growth inhibition by GIA activity, or a difference in
their IFN-c production by ELISPOT.
Generalizability
While the three vaccine candidates induced high concentrations
of anti-AMA-1 antibodies which exhibited functional activity,
albeit only against a homologous allele, it remains unclear if and at
what level a monovalent 3D7-based AMA-1 vaccine will stimulate
cross-reactive antibodies in malaria-experienced populations. The
mean percent inhibition by GIA seen in Malian adults vaccinated
with AMA-1/AS02A was greater against both 3D7 and FVO
parasites than control vaccinees [17]. Nonetheless, a successful
AMA-1-based vaccination strategy may need to include more than
one AMA-1 allele to be effective in populations continually
exposed to malaria infection [43]. Studies of AMA-1 diversity over
three years in Bandiagara, Mali are finding extreme diversity, with
no single haplotype having a prevalence of more than 4%. The
3D7 allele represents one of the most common AMA-1 haplotypes,
and no parasites carry the full FVO haplotype in this setting (S.
Takala, personal communication). Testing of AMA-1/AS02A in a
pediatric Phase 2b, placebo-controlled trial in Bandiagara, Mali,
an epidemiologic setting of substantial AMA-1 allelic diversity, is
currently ongoing (www.clinicaltrials.gov NCT00460525). In
addition to the primary efficacy endpoint of clinical malaria,
planned ancillary analyses will explore both parasitologic and
allele-specific effects, thus evaluating the potential for a 3D7
AMA-1-based vaccine to induce a cross-protective immune
response in a malaria-experienced population, as well as the
possibility that ongoing natural exposure will boost heterologous
allele-specific responses.
Our AMA-1-based malaria vaccine development strategy
requires that two sequential milestones be accomplished prior to
incorporation of one or more AMA-1 antigens into a multi-stage,
multi-component vaccine [22]. First, an AMA-1 vaccine must
confer significant clinical benefit in either a Phase 2a malaria
challenge or in an endemic population. Second, the AMA-1
vaccine must be sufficiently active against diverse AMA-1 alleles
such that the risk of allelic escape is very low. In anticipation of the
potential requirement for inclusion of additional AMA-1 alleles in
a multi-antigen vaccine, we have produced GMP AMA-1
representing the FVO allele and anticipate potentially combining
the two FVO and 3D7 antigens in a vaccine. Allelic exchange
experiments have recently defined specific clusters of polymorphic
amino acid residues involved in antigenic escape in vitro [43], and
studies of the within-host dynamics of blood stage antigens offer
another strategy for identifying specific residues associated with
allele-specific clinical immunity [44]. Current research efforts at
WRAIR seek to identify a consensus AMA-1 molecule/chimera
that would elicit a broad immunity active against multiple P.
falciparum AMA-1 phenotypes [43].
Overall Evidence
Since AMA-1 is expressed on pre-erythrocytic and erythrocytic
stages of the parasite, it is a promising vaccine antigen to induce
malarial protection by targeting both the humoral and cell-
mediated arms of the immune system. Both types of immune
responses have been demonstrated in this study, in three other
vaccine trials with AMA-1/AS02A [16,17,34] as well as an AMA-
1 protein antigen formulated in alum [27] and Montanide ISA
720 [34]. This study was the first to test the efficacy of AMA-1;
subjected to a stringent test of efficacy that required treatment at
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infection or delayed patency, but one formulation, AMA-1/
AS02A, did suggest a significant reduction in parasite burden as
determined by PCR analysis. Current field trials now underway in
Bandiagara, Mali should provide additional data to potentially
determine if the immunogenicity results seen will translate into
significant clinical effect in a population living in a malaria
endemic area with a diverse parasite population.
That AMA-1 continues to be thought of as a promising vaccine
antigen is reflected in its recent testing in an adenovector-based
platform (personal communication Thomas Richie) and in
virosomes [45]. With the new goal of malaria eradication set
forth by World Health Organization and the upcoming large scale
pediatric Phase 3 study of RTS,S in subSaharan Africa, an
effective second generation malaria vaccine is critical. Based on
the present trial’s evidence of strong immunogenicity of AMA-1/
AS01B and AS02A and the encouraging suggestion of biological
effect, we believe AMA-1 remains a viable vaccine candidate.
Future studies will help elucidate whether modification or addition
of allelic forms and/or choice of delivery platform may sufficiently
enhance its immunogenicity and efficacy to protect the most
vulnerable populations.
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